Patents Represented by Attorney Maynard R. Johnson
-
Patent number: 4870101Abstract: Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-di-isobutyl-6-(N,N-dimethylaminomethyl)-phenol.Type: GrantFiled: February 18, 1988Date of Patent: September 26, 1989Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: George Ku, Niall Doherty
-
Patent number: 4543221Abstract: Improved cellulose semipermeable hollow fibers useful in detoxifying blood during hemodialysis or hemofiltration treatments. The cellulose fibers are fine, capillary fibers that are made by melt extrusion of certain cellulose ester polyol melt spin compositions into self-supporting gelled fibers. The cellulose ester gelled fibers are subsequently chemically converted into cellulose fibers by deacetylation, in aqueous alkali solution. The product fibers exhibit improved wet intrinsic tensile strength and higher water permeability characteristics than heretofore known cellulose fibers made from cellulose ester spin compositions.The invention includes the method of making the improved fibers and separatory cells such as hemodialyzers or hemofilters which contain the improved fibers in a gamma ray sterilized condition.Type: GrantFiled: October 21, 1981Date of Patent: September 24, 1985Assignee: CD Medical, Inc.Inventors: David T. Chen, Robert D. Mahoney
-
Patent number: 4526890Abstract: 3,6,7,8-Substituted-s-triazolo-pyridazine compounds such as 7,8-dimethyl-6-morpholino-3-methyl-s-triazolo[4,3-b]pyridazine or 7,8-dimethyl-6-(1-pyrrolidinyl)-3-(isopropyl)-s-triazolo-[4,3-b]pyridazine are prepared by the reaction of a carboxylic acid with a substituted 3-hydrazino-6-halo-pyridazine followed by the reaction of the resulting 6-halotriazolopyridazine with a corresponding base. The compounds have pharmacological activity as bronchodilators.Type: GrantFiled: April 7, 1981Date of Patent: July 2, 1985Assignee: The Dow Chemical CompanyInventors: Norton P. Peet, Shyam Sunder
-
Patent number: 4459302Abstract: New acyl-1H-1,2,4-triazole derivatives of the formula ##STR1## wherein R may be located on one of the two adjacent nitrogen atoms and may represent hydrogen; a group R.sub.5 -CO wherein R.sub.5 is selected from (C.sub.1-4)alkyl, (C.sub.2-4)alkenyl, (C.sub.2-4)alkynyl, phenyl, phenyl substituted by one to three groups independently selected from halo, (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy, trifluoromethyl, cyano, nitro, amino, di-(C.sub.1-4)alkylamino, (C.sub.2-4)acylamino and methylenedioxy, benzyl, cinnamyl, amino, (C.sub.1-4)alkylamino, di-(C.sub.1 -C.sub.4)alkylamino, phenylamino, phenylamino wherein the phenyl ring may be substituted by one to three groups independently selected from halo, (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy, trifluoromethyl, cyano, nitro, amino, di-(C.sub.1-4)alkylamino, (C.sub.2-4)acylamino and methylenedioxy, halo(C.sub.1-4)alkyl, (C.sub.1-4)alkoxy and benzyloxy;a group R.sub.6 -SO.sub.2 wherein R.sub.6 may represent (C.sub.Type: GrantFiled: October 23, 1979Date of Patent: July 10, 1984Assignee: Gruppo Lepetit, S.p.A.Inventors: Amedeo Omodei-Sale, Pietro Consonni, Giulio Galliani
-
Patent number: 4271155Abstract: The invention relates to new water soluble 3-formylrifamycin SV hydrazones wherein the hydrazone moiety contains a phosphonoxy lower alkyl radical which imparts water solubility. The compositions containing said rifamycin derivatives are also an object of this invention. The new rifamycin derivatives and their pharmaceutical compositions are particularly suitable for parenteral administration.Type: GrantFiled: June 19, 1980Date of Patent: June 2, 1981Assignee: Gruppo Lepetit S.p.A.Inventor: Renato Cricchio
-
Patent number: 4072565Abstract: Growth of cells in tissue culture and virus vaccine production in tissue culture in the absence of serum are disclosed. The cells in tissue culture are grown initially in a chemically defined medium containing protamine zinc insulin, and the protamine zinc insulin medium is removed before virus propagation. Supplementation with serum or serum fractions can be eliminated entirely; and improved virus production in a serum free system can be obtained.Type: GrantFiled: November 4, 1974Date of Patent: February 7, 1978Assignee: The Dow Chemical CompanyInventors: Stefan A. Weiss, Harry L. Torney, William J. Caldwell
-
Patent number: 4067998Abstract: 2-((3,5-Di-tert-butylphenyl)thio) alkanoic acids and ester derivatives and pharmaceutically-acceptable salts thereof are disclosed; pharmaceutical compositions containing said compounds and methods of reducing plasma lipid levels in mammals are also provided.Type: GrantFiled: February 13, 1975Date of Patent: January 10, 1978Assignee: The Dow Chemical CompanyInventor: Eugene R. Wagner
-
Patent number: 4066771Abstract: Quaternary ammonium compounds such as [2-(4-amino-2,6-dibromophenoxy)ethyl]dimethyl (allyl) ammonium bromide are prepared by the reaction of a tertiary amine such as 3,5-dibromo-.beta.-dimethylamino-p-phenetidine with a substituted organic compound such as allyl bromide. The quaternary ammonium compounds are useful in alleviating or inhibiting cardiac arrhythmias when the quaternary ammonium compounds, or compositions comprising the same are administered to animals.Type: GrantFiled: January 12, 1976Date of Patent: January 3, 1978Assignee: The Dow Chemical CompanyInventor: Stanley J. Strycker
-
Patent number: 4049814Abstract: Quaternary ammonium compounds such as [2-(4-amino-2,6-dibromophenoxy)ethyl]dimethyl (allyl) ammonium bromide are prepared by the reaction of a tertiary amine such as 3,5-dibromo-.beta.-dimethylamino-p-phenetidine with a substituted organic compound such as allyl bromide. The quaternary ammonium compounds are useful in alleviating or inhibiting cardiac arrhythmias when the quaternary ammonium compounds, or compositions comprising the same are administered to animals.Type: GrantFiled: January 12, 1976Date of Patent: September 20, 1977Assignee: The Dow Chemical CompanyInventor: Stanley J. Strycker
-
Patent number: 4042692Abstract: Quaternary ammonium compounds such as [2-(4-amino-2,6-dibromophenoxy)ethyl]dimethyl (allyl) ammonium bromide are prepared by the reaction of a tertiary amine such as 3,5-dibromo-.beta.-dimethylamino-p-phenetidine with a substituted organic compound such as allyl bromide. The quaternary ammonium compounds are useful in alleviating or inhibiting cardiac arrhythmias when the quaternary ammonium compounds, or compositions comprising the same are administered to animals.Type: GrantFiled: January 12, 1976Date of Patent: August 16, 1977Assignee: The Dow Chemical CompanyInventor: Stanley J. Strycker
-
Patent number: 4042712Abstract: Quaternary ammonium compounds such as [2-(4-amino-2,6-dibromophenoxy)ethyl]dimethyl (allyl) ammonium bromide are prepared by the reaction of a tertiary amine such as 3,5-dibromo-8-dimethylamino-p-phenetidine with a substituted organic compound such as allyl bromide. The quaternary ammonium compounds are useful in alleviating or inhibiting cardiac arrhythmias when the quaternary ammonium compounds, or compositions comprising the same are administered to animals.Type: GrantFiled: January 12, 1976Date of Patent: August 16, 1977Assignee: The Dow Chemical CompanyInventor: Stanley J. Strycker
-
Patent number: 4042709Abstract: Quaternary ammonium compounds such as [2-(4-amino-2,6-dibromophenoxy)ethyl]dimethyl (allyl) ammonium bromide are prepared by the reaction of a tertiary amine such as 3,5-dibromo-.beta.-dimethylamino-p-phenetidine with a substituted organic compound such as allyl bromide. The quaternary ammonium compounds are useful in alleviating or inhibiting cardiac arrhythmias when the quaternary ammonium compounds, or compositions comprising the same are administered to animals.Type: GrantFiled: January 12, 1976Date of Patent: August 16, 1977Assignee: The Dow Chemical CompanyInventor: Stanley J. Strycker
-
Patent number: 4041178Abstract: Quaternary ammonium compounds such as [2-(4-amino-2,6-dibromophenoxy)ethyl]dimethyl (allyl) ammonium bromide are prepared by the reaction of a tertiary amine such as 3,5-dibromo-.beta.-dimethylamino-p-phenetidine with a substituted organic compound such as allyl bromide. The quaternary ammonium compounds are useful in alleviating or inhibiting cardiac arrhythmias when the quaternary ammonium compounds, or compositions comprising the same are administered to animals.Type: GrantFiled: January 12, 1976Date of Patent: August 9, 1977Assignee: The Dow Chemical CompanyInventor: Stanley J. Strycker
-
Patent number: 4029703Abstract: N,N'-Disubstituted halophenylacetamidine compounds such as N,N'-dimethyl-3,4-dichlorophenyl-acetamidine, and their pharmaceutically-acceptable salts are prepared by the reaction of a substituted phenylacetonitrile with an alkylamine and alkylammonium salt or alternatively, by reaction of the acetonitrile or corresponding N-alkylphenylacetamide with a trialkyloxonium fluoroborate followed by reaction with a primary alkylamine.The compounds have pharmacological activity as antidepressants and antianxiety or calming agents.Type: GrantFiled: February 11, 1976Date of Patent: June 14, 1977Assignee: The Dow Chemical CompanyInventor: James R. McCarthy, Jr.
-
Patent number: 4024021Abstract: Glutamate and glutamic transaminases are determined by mixing a substrate-reagent composition that is essentially free of ammonia or ammonium ions with a specimen to be analyzed, incubating the resulting mixture for less than about 15 minutes, terminating incubation and measuring a color produced.Type: GrantFiled: May 9, 1975Date of Patent: May 17, 1977Assignee: The Dow Chemical CompanyInventors: William S. Stavropoulos, Kenneth J. Acuff
-
Patent number: 4016162Abstract: 6-Morpholino-3-substituted phenyl triazolopyridazine compounds such as 8-methyl-6-morpholino-3-phenyl-s-triazolo[4,3-b]pyridazine or 8-methyl-6-morpholino-3-(3,4,5-trimethoxyphenyl)-s-triazolo[4,3-b]pyridazi ne are prepared by the reaction of the corresponding substituted benzoyl halide with a 3-hydrazino-6-morpholinopyridazine in the presence of a hydrogen chloride acceptor or by the reaction of a 3-halo-6-morpholinopyridazine with a corresponding substituted benzoyl hydrazide. The compounds have pharmacological activity as bronchodilators.Type: GrantFiled: April 8, 1976Date of Patent: April 5, 1977Assignee: Gruppo Lepetit S.p.A.Inventors: Elvio Bellasio, Ambrogio Campi
-
Patent number: 4001089Abstract: A novel reagent and method for colorimetrically determining the concentration of triglycerides in biological fluids, and for rapid determination of glycerol are described. Triglycerides are hydrolyzed in methanolic base to glycerol, and glycerol content is determined colorimetrically.Type: GrantFiled: March 20, 1974Date of Patent: January 4, 1977Assignee: The Dow Chemical CompanyInventors: William S. Stavropoulos, Robert D. Crouch
-
Patent number: 3991210Abstract: The disclosure relates to a method useful for combating microorganisms associated with infections of the urinary tract in mammals by means of administering to mammals an amount of a substituted acetamidine compound such as 2-(4-bromophenyl) acetamidine or a pharmacologically-acceptable salt thereof sufficient to provide an antiseptic amount of said compound in the urinary tract or in the urine and compositions useful in practicing the method.Type: GrantFiled: May 5, 1975Date of Patent: November 9, 1976Assignee: The Dow Chemical CompanyInventor: Philip J. Shea
-
Patent number: 3989613Abstract: A continuous balanced flow electrophoresis apparatus utilizes a fixed, colloid-permeable boundary membrane across which net liquid flow is minimized. The apparatus is employed in electrophoretic separation of colloids such as blood plasma proteins in which fluid flow rates are controlled and balanced to minimize or prevent liquid transfer across the boundary membrane.Type: GrantFiled: May 16, 1973Date of Patent: November 2, 1976Assignee: The Dow Chemical CompanyInventor: Gerhard Gritzner
-
Patent number: 3988474Abstract: A method useful for alleviating central nervous system depression comprises administration to animals of an effective amount of an N,N'-dialkyl-halobenzamidine. Compositions useful in practicing the method are also disclosed.Type: GrantFiled: September 23, 1975Date of Patent: October 26, 1976Assignee: The Dow Chemical CompanyInventors: Abdulmuniem H. Abdallah, Philip J. Shea